Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Share-based Compensation (2022 - 2025)

Praxis Precision Medicines has reported Share-based Compensation over the past 4 years, most recently at $9.9 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $9.9 million for Q4 2025, up 15.9% from a year ago — trailing twelve months through Dec 2025 was $33.9 million (down 17.94% YoY), and the annual figure for FY2025 was $33.9 million, down 17.94%.
  • Share-based Compensation for Q4 2025 was $9.9 million at Praxis Precision Medicines, up from $7.4 million in the prior quarter.
  • Over the last five years, Share-based Compensation for PRAX hit a ceiling of $14.5 million in Q1 2024 and a floor of $5.7 million in Q4 2023.
  • Median Share-based Compensation over the past 4 years was $7.6 million (2022), compared with a mean of $8.0 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 115.72% in 2024 and later tumbled 40.1% in 2025.
  • Praxis Precision Medicines' Share-based Compensation stood at $6.4 million in 2022, then fell by 10.05% to $5.7 million in 2023, then surged by 49.76% to $8.6 million in 2024, then grew by 15.9% to $9.9 million in 2025.
  • The last three reported values for Share-based Compensation were $9.9 million (Q4 2025), $7.4 million (Q3 2025), and $7.8 million (Q2 2025) per Business Quant data.